• Acquisition price of A$7.40 per share in cash
• Consideration represents a significant premium to the pre-announcement share price
• The Mayne Pharma Board unanimously recommends that shareholders vote in favour of the Scheme

Mayne Pharma Group Limited (ASX: MYX) has entered into a scheme implementation deed with Cosette Pharmaceuticals, Inc. under which Cosette has agreed to acquire 100% of the shares in Mayne Pharma by way of a Scheme of Arrangement at a price of A$7.40 per share. Cosette is a US-based pharmaceutical company with a portfolio of products in women's health and dermatology. The Scheme Consideration of A$7.40 per share values Mayne Pharma's equity at approximately A$672 million and represents a premium of 37% to Mayne Pharma's closing share price as at 20 February 2025, a 42% premium to the 30-day VWAP, a 50% premium to the 90-day VWAP, and a 57% premium to the 180-day VWAP. The Scheme is fully funded and subject to limited customary conditions, including various regulatory approvals, approval by Mayne Pharma shareholders at the Scheme meeting, and Court approval. The Mayne Pharma Board unanimously recommends that Mayne Pharma shareholders vote in favour of the Scheme, in the absence of a Superior Proposal and subject to an independent expert concluding that the Scheme is in the best interests of Mayne Pharma shareholders.